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Abstract:							Tracking	the	migration	of	superparamagnetic	iron	oxide	(SPIO)	labeled	immune	cells	in	vivo	is	valuable	for	understanding	the	immunogenic	response	to	cancer	and	therapies.		While	many	sequences	are	sensitive	to	SPIO	contrast,	they	lack	specificity	and	 provide	 only	 semi-quantitative	 information.	 Quantitative	 cell	 tracking	 using	compressed	 sensing	 TurboSPI-based	 R2*	 mapping	 is	 a	 promising	 development	 to	improve	 accuracy	 in	 longitudinal	 studies	 on	 immune	 recruitment.	 The	 phase-encoded	 TurboSPI	 sequence	 provides	 high	 fidelity	 relaxation	 data	 in	 the	 form	 of	signal	 time-courses	 with	 high	 temporal	 resolution.	 However,	 early	 in	 vivo	applications	 of	 this	 method	 revealed	 that	 simple	 mono-exponential	 R2*	 fitting	performs	poorly	due	to	the	contaminant	fat	signal	in	voxels	surrounding	regions	of	interest,	 such	as	 flank	 tumors	and	 lymph	nodes	adjacent	 to	adipose	 tissue.	This	 is	especially	problematic	if	there	is	poor	infiltration	to	the	tumor	such	that	immune	cells	remain	near	the	periphery.	The	presence	of	an	off-resonance	fat	isochromat	results	in	modulations	in	the	signal	time-course	can	be	erroneously	fit	as	R2*	signal	decay,	thereby	overestimating	the	density	of	SPIO	labeled	cells.		Simply	excluding	any	voxel	with	 fat-typical	 modulations	 results	 in	 underestimates	 in	 voxels	 that	 have	 mixed	content.	We	propose	using	a	more	comprehensive	dual-decay	(R2f*	and	R2w*)	Dixon-based	signal	model	that	accounts	for	the	potential	presence	of	fat	in	a	voxel	to	better	estimate	SPIO	induced	de-phasing.	In	silico	single	voxel	simulations	illustrate	how	the	proposed	 signal	 model	 provides	 stable	 R2w*	 estimates	 that	 are	 invariant	 to	 fat	content.	 The	 proposed	 dual-decay	 model	 outperforms	 previous	 methods	 when	applied	 to	 in	 vitro	 samples	of	 SPIO	 labeled	 cells	 and	oil	 prepared	with	oil	 content	≥15%.	 	 Preliminary	 in	 vivo	 results	 show	 that,	 compared	 to	 previous	methods,	 the	dual-decay	Dixon	model	 improves	 the	 balance	 of	R2*	 specificity	 versus	 sensitivity,	which	in	turn	will	result	in	more	reliable	analysis	in	future	cell	tracking	studies.																						
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Introduction:			 Immunotherapies	are	a	rapidly	growing	field	of	cancer	treatments	that	have	had	varying	degrees	of	success	in	the	clinic1,2.	Using	imaging	to	track	the	migration	of	immune	 cells	 in	 response	 to	 both	 cancer	 and	 cancer	 therapies	 is	 valuable	 for	understanding	 the	 underlying	 immunogenic	 mechanisms,	 particularly	 when	 used	longitudinally.	 Analyzing	 immune	 cell	 recruitment	 is	 especially	 important	 when	studying	 immunotherapies,	which	do	not	 always	 fit	 traditional	metrics	 of	 therapy	success3,4;	alternative	metrics	based	on	immune	activity	may	be	more	relevant.	MRI	is	one	of	the	most	promising	modalities	for	immune	cell	tracking	due	to	its	 high	 resolution,	 lack	 of	 invasiveness	 and	 good	 sensitivity	 with	 choice	 of	appropriate	contrast	agent.	Superparamagnetic	iron-oxide	nanoparticles	(SPIO)	are	the	most	popular	MRI	contrast	agent	for	cell	tracking5-8.	SPIO-labeled	cells	are	often	imaged	using	a	balanced	steady	state	free	precession	(bSSFP)	sequence5-9,	which	is	ideal	for	its	high	SNR	and	sensitivity	to	SPIO	effects10.	Unfortunately,	there	are	well-documented	challenges	associated	with	tracking	SPIO-labeled	cells11.	For	example,	specificity	issues	arise	when	endogenous	sources	of	negative	contrast,	such	as	tumor	necrosis	(Figure	1	from	12,	detailed	methods	in	supplementary	 methods),	 are	 misinterpreted	 as	 the	 hypo-intense	 signal	 voids	associated	 with	 clusters	 of	 labeled	 cells.	 Accounting	 for	 false	 positives	 requires	integration	with	biological	 techniques	 (via	 tumor	necropsy	and	histochemistry)	 to	validate	 findings	 for	 each	 subject,	 which	 is	 difficult	 to	 scale	 to	 large	 studies	 and	eliminates	the	possibility	of	longitudinal	studies.		Quantification	 is	 another	 challenge	 for	MRI	 cell	 tracking	 applications	 since	sequences	like	bSSFP	enable	only	qualitative	analysis	of	changes	in	image	contrast.	The	 analysis	 can	 become	 semi-quantitative	 by	 comparing	 the	 signal	 intensity	histograms	before	and	after	labeled	cell	injection13	or	using	a	matched	control7,	but	these	methods	offer	only	relative	quantification.	Relaxation	rate	mapping	is	a	popular	method	for	attempting	to	quantify	SPIO	labeled	cells,	since	R2*	(R2*	=	1/T2*)	increases	linearly	 as	 a	 function	 of	 cell	 density14,15.	 However,	many	 R2*	mapping	 techniques	proposed	 to	 date	 are	 unable	 to	 resolve	 rapidly	 decaying	 signals	 restricting	quantitative	 dynamic	 range,	 and	 prone	 to	 blooming	 artifacts	 induced	 by	 the	 very	species	which	they	are	intended	to	quantify16,17.	Fluorine-19	 (19F)	 based	methods	 address	 some	of	 these	 issues18-20,	 but	 the	gains	are	countered	by	a	significant	decrease	in	sensitivity	compared	to	proton	MRI	19,	thereby	requiring	far	more	injected	cells,	larger	numbers	of	cells	being	recruited	to	regions	of	interest,	or	a	higher	concentration	of	19F	to	be	localized	within	cells.	Previous	 preclinical	 work	 done	 by	 our	 lab	 demonstrated	 the	 use	 of	 3D	TurboSPI,	adapted	for	quantifying	labeled	cells16,17.	TurboSPI	is	an	accelerated	multi-echo	single	point	imaging	(SPI)	sequence	that	was	first	developed	for	porous	media	with	 short	 T2*	 relaxation	 times	 (~1ms).	 This	 sequence	 produces	 high	 temporal	resolution	data	(sampled	at	~100	kHz)	which	enables	high	fidelity	R2*	mapping	with	greater	 dynamic	 range	 and	 fewer	 artifacts	 due	 to	 the	 purely	 phase-encoded	acquisition16,17,21,22.	While	the	initial	TurboSPI	studies	proved	promising,	a	pilot	preclinical	in	vivo	study	 that	 compared	multiple	 immunotherapy	 treatment	groups12	 revealed	a	new	
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potential	source	of	error:	the	presence	of	off-resonance	fat	modulations	in	the	signal	time	 course.	 Since	 the	 original	 analysis	 used	 a	 simple	mono-exponential	model	 to	estimate	 the	 R2*	 relaxation	 parameter,	 fat	 signal	modulations	 can	 falsely	 indicate	elevated	 signal	 decay,	 resulting	 in	 apparent	 regions	 of	 elevated	 R2*	 decay	 falsely	appearing	 as	 elevated	 SPIO-labeled	 cell	 density.	 That	 is,	 one	 specificity	 issue	was	traded	for	another	in	the	form	of	false	positives	from	fat.	These	errors	are	especially	problematic	 near	 the	 fat	 pads	 at	 the	 tumor	 periphery	 and	 lymph	 nodes,	 areas	 of	potentially	 high	 cell	 recruitment	 (Figure	 2	 from	 12,	 detailed	 methods	 in	supplementary	methods).	The	larger	voxels	necessitated	by	SPI	can	result	in	mixed	content	of	fat	and	SPIO	labeled	cells,	such	that	the	associated	time	course	will	reflect	both	 types	 of	 signal	 evolution.	 Masking	 out	 voxels	 whose	 time	 course	 contains	modulations	at	the	typical	lipid	frequency	(447	Hz)	will	eliminate	fat-contaminated	voxels	from	the	map,	but	this	leads	to	underestimates	in	cell	numbers.	More	robust	analysis	to	accommodate	voxels	containing	both	labeled	cells	and	fat	is	required.	In	this	work,	we	propose	a	modified	Dixon-based	signal	model	that	simultaneously	estimates	R2*	and	fat	fraction	to	improve	fitting	accuracy,	such	that	R2*	 can	be	quantified	 independent	of	 the	 fat	 content	within	a	voxel.	The	 converse	problem	 has	 been	 investigated	 previously	 in	 the	 literature;	 for	 example,	 Yu23,	O’Regan24,	Chebrolu25	and	Reeder26	obtained	accurate	information	of	fat	content	in	the	liver,	regardless	of	R2*	effects	from	hepatic	iron.	However,	this	is	the	first	attempt	to	address	the	problem	of	improving	the	accuracy	of	R2*	estimates	in	TurboSPI	in	the	presence	of	fat.		This	work	begins	with	an	in	silico	investigation	to	characterize	the	problem,	an	
in	vitro	experiment	to	validate	the	improved	fitting	scheme	on	real	data,	and	finally	a	preclinical	in	vivo	test	on	a	mouse	injected	with	SPIO	labeled	cells.		
Experimental:			
Models	Used:	
													Three	 fitting	models/techniques	were	 compared	 in	 these	 experiments.	 The	simplest	method	is	a	mono-exponential	single	species	(water)	decay	model	(Eq.	1),	or	“single-decay”	technique.	 	This	method	simply	fits	 the	magnitude	portion	of	 the	signal	decay	as			𝑆 = 𝑊𝑒%&'/)*∗ 																																																																																				[Eq.	1]		 														W	is	the	signal	amplitude	for	the	water	isochromat	and,	T2*	is	the	decay	rate	of	water.	Dt	is	the	difference	in	time	between	the	centre	of	the	spin-echo	peak	and	the	data	acquisition.	The	second	technique	attempts	to	address	fat	voxels	by	performing	a	post-acquisition	 fat	exclusion	combined	with	 the	single-decay	model,	henceforth	referred	 to	 as	 the	 “exclusion”	 technique.	 During	 the	 fitting	 process,	 the	 algorithm	identifies	 modulations	 in	 the	 time-course	 that	 have	 fat-specific	 periodicity,	 and	excludes	these	voxels	from	the	analysis,	i.e.	sets	R2*	=	0	for	each	of	those	voxels.	For	the	exclusion	criteria,	fat	is	identified	when	the	signal	phase	changes	non-uniformly	around	TE	+	1.1ms,	i.e.	when	the	fat	and	water	signals	are	out	of	phase.	This	technique	
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was	 previously	 applied	 to	 in	 vivo	 data	 but	 is	 unable	 to	 address	 “mixed	 voxels”	containing	both	fat	and	SPIO	labeled	cells12.													The	third	technique	is	the	proposed	model:	modified	dual-decay	Dixon,	or	the	“dual-decay”	 technique,	which	 simultaneously	estimates	 the	 fat	 fraction	as	well	 as	separate	R2*	relaxation	rates	for	fat	and	water	(Eq.	2).		S	 = 	We0(234	5	36&')e%&'/8*9∗ + 	Fe0(3<	5	&29=&')e%&'/)*=∗ 									[Eq.	2]													 W,	F,	θw	θf	are	signal	amplitudes	and	phases	for	the	water	and	fat	isochromats,	respectively,	T2w*	and	T2f*	are	separate	decay	rates	for	the	water	and	fat	species,	Δωwf		is	 the	 frequency	 offset	 between	 the	 isochromats,	 and	θτ	 is	 a	 slow	 time	dependent	phase	change	due	to	the	SPIO26,27.													Dual-T2*	 Dixon	models	 have	 been	 used	 in	 the	 literature	 for	 other	 purposes.	Chebrolu25	and	O’Regan24	investigated	using	independent	T2*	estimates	to	improve	fat	 quantification,	 and	 Horng28	 and	 Reeder26	 compared	 methods	 that	 use	 T2*	 to	correct	fat	quantification.	Replacing	a	common	T2*	with	independent	fat	and	water	T2*	 values	 has	 been	 debated	 in	 the	 literature.	 Chebrolu	 found	 that	 using	 dual	 T2*	correction	methods	reduces	error,	especially	 in	phantoms	with	high	 levels	of	both	SPIO	and	fat25	since	the	SPIO	has	a	greater	T2*	effect	on	water	than	fat.		
	
In	Silico	Investigation	and	Model	Development:	
In	silico	analyses	were	performed	to	investigate	the	combined	effects	of	R2*	decay	and	fat	modulations.		All	aspects	of	the	in	silico	work	were	implemented	using	customized	in-house	Matlab	2017b	code	(Mathworks,	Natick,	MA).	The	TurboSPI	signal	was	first	simulated	without	fat	contributions	using	Monte	Carlo	methods,	 which	 are	 described	 in	more	 detail	 elsewhere28-30.	 	Briefly,	 water	molecules	 diffuse	 through	 a	 randomly	 distributed	 grid	 of	 spherical	magnetic	 field	perturbers	 of	 defined	 size,	 susceptibility	 and	 volume	 fraction.	 The	magnetic	 field	experienced	by	each	proton	is	calculated	at	each	time	step	to	track	the	accumulated	phase.		The	echo	time	(TE),	repetition	time	(TR),	and	sampling	rate	were	matched	to	the	 TurboSPI	 sequence	 used	 for	 in	 vitro	 and	 in	 vivo	 experiments.	 The	 result	 is	 a	complex	magnetization	time	course	computed	from	the	excitation	pulse	through	the	spin	echo	to	t=3TE/2.		N=30	000	independent	simulations	were	summed	to	give	the	final	 signal,	 an	example	of	which	 is	 shown	 in	Figure	3	with	 the	 typical	acquisition	window	(for	in	vitro/in	vivo	data)	highlighted.	T2	relaxation	was	simulated	to	be	long	(1s),	a	reasonable	simplification	since	T2	>>	T2*	for	SPIO	compartmentalized	in	cells29.							 In	this	work,	a	simplified	single	peak	lipid	model	with	the	common	chemical	shift	of	3.5	ppm	(Δfwf		=447	Hz	at	3T)	is	added	to	the	simulations.	The	signal	from	fat	(Sf	=	e^{-i2π(γBo-Δfwf)t}	was	added	to	the	simulated	TurboSPI	signal	for	various	fat	fractions	(ff	=	0	to	100%	in	steps	of	5%)	to	represent	lipid	contributions	(Figure	3).		Rather	than	estimating	fat	fraction	separately	to	correct	the	R2*	measurement,	both	parameters	are	estimated	simultaneously	using	the	dual	decay	model	[Eq.	2].			Presently,	the	fit	is	only	performed	on	the	portion	of	the	decay	from	t	=	10.5	ms	to	t	=	12.5	ms.	This	is	to	avoid	the	spin	echo	peak	at	TE	=	10	ms,	near	which	there	exists	 a	 deviation	 from	 the	model’s	 predicted	 exponential	 decay	 (the	 presence	 of	
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diffusion	gives	 rise	 to	non-exponential	 signal	 attenuation30).	Away	 from	 t=TE,	 this	additional	factor	approaches	unity	and	the	proposed	model	becomes	valid.						 The	real	and	imaginary	channels	were	concatenated	and	fit	as	a	single	unit	to	accommodate	 bounded	 optimization	 using	 Matlab’s	 lsqcurvefit,	 which	 does	 not	support	bounds	for	complex	inputs.		Data	were	simulated	and	fit	with	a	range	of	fat	fractions	 from	0	 to	1,	 to	demonstrate	stability	 in	 the	T2*	measurement,	and	with	a	range	of	perturber	volume	fractions	to	ensure	stability	with	respect	to	cell	density.		Estimated	fat	fractions	were	compared	to	the	known	input,	and	estimated	T2*w	values	were	compared	to	the	gold	standard	value	obtained	from	fitting	a	mono-exponential	decay	with	no	added	fat.		
In	Vitro	Experiment	Images	were	acquired	using	phantoms	prepared	with	equal	concentrations	of	SPIO-labeled	cells,	but	varying	 fat	 fractions	and	 two	 “no	cell”	 controls.	 	Cells	were	isolated	from	C57BL/6	mice	obtained	from	Charles	River	Laboratories	(St.	Constant,	PQ);	all	procedures	adhered	to	approved	ethics	protocols	for	animal	care	according	to	the	University	Committee	on	Laboratory	Animals,	Dalhousie	University.	CTLs	were	harvested	from	the	inguinal,	mesenteric,	brachial,	axillary,	and	submandibular	lymph	nodes	from	C57BL/6	mice,	cultured	according	to	internal	protocols	over	8	days,	and	loaded	with	Rhodamine	B	SPIO	nanoparticles	 (30	nm,	Biopal,	Worcester	MA)	 to	a	concentration	of	5	pg/cell	using	passive	in	vitro	incubation	for	24	hours.	Solutions	 of	 SPIO-labeled	 cells,	 water,	 and	 peanut	 oil	were	 suspended	 in	 a	polyacrylamide	gel	and	placed	in	5	mm	NMR	tubes.	The	gel	contained	10%	sodium	dodecyl	 sulfate,	 40%	 acrylamide,	 1M	 hydroxyethyl	 piperazineethanesulfonic	 acid	(HEPES),	10%	ammonium	persulfate,	 and	 tetramethylethylenediamine.	 	Nine	 such	phantoms	were	created;	seven	with	SPIO	labeled	cells	(fat	content	=	0,	5,	10,	15,	20,	30,	 40	%)	 and	 two	 controls	with	no	 cells	 (20,	 40%	 fat).	 The	phantoms	with	 SPIO	labeled	 cells	 contained	 a	 constant	 concentration	 of	 2	 x	 106	 SPIO	 loaded	 CD8+	 T	lymphocytes	(CTLs)	per	1	mL	solution.			All	MR	data	were	 acquired	 using	 a	 3	 Tesla	 horizontal	 bore	 pre-clinical	MR	scanner	(Oxford,	UK,	console	by	Agilent,	Santa	Clara,	CA).	For	 imaging,	NMR	tubes	were	placed	 inside	a	cylindrical	MR-transparent	phantom	holder	 filled	with	doped	water	(160	x10-6	M	MnCl2).		Samples	were	imaged	in	sets	of	three	using	a	2D	TurboSPI	sequence17	 (TR=250	ms,	 TEeffective	 =	 10	ms,	 ETL=8,	 ESP=10ms,	matrix	 =	 128x128,	FOV=50	x	50	mm2,	 scan	 time	8.5	min)	with	and	without	a	 chemically-selective	 fat	saturation	pulse	(90°	sinc).	Signal	time	course	data	were	fit	for	each	voxel	using	the	exclusion	method12,	and	dual-decay	model	(Eq.	2).	When	fitting	in	vitro	data,	the	time	dependent	variables	θτ	and	Δωwf	also	incorporate	the	effects	of	Bo	inhomogeneity,	without	 the	 need	 for	 a	 separate	 fitting	 parameter.	 While	 both	 T2w*	 and	 T2f*	 are	estimated,	it	is	R2W*	=1/T2w*	that	is	reported	in	the	final	maps.			
In	Vivo	Experiment	On	Day	0,	C57BL/6	mice	received	a	subcutaneous	injection	of	C3	cells	from	the	murine	cervical	cancer	C3	cell	line7,31,32	(5	x	105	cells	in	100	μL	in	the	left	flank).	CTLs	were	again	harvested	 from	the	 inguinal,	mesenteric,	brachial,	axillary,	and	submandibular	lymph	nodes	of	disease	matched	donor	mice	(implanted	Day	-7),	
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isolated	 and	 cultured	 according	 to	 internal	 protocols	 (Day	 12-Day	 19).	 CTLs	were	primed,	 using	 antigen	 presenting	 cells	 (APCs)	 at	 a	 ratio	 of	 1:10	 APCs:CTLs,	 to	recognize	the	R9F	antigen	of	C3	cells7,	thereby	promoting	cellular	recruitment.	The	CTLs	were	loaded	with	SPIO	nanoparticles	on	Day	19	(30	nm,	Biopal,	Worcester	MA)	and	8x106	SPIO	 labeled	CTLs	were	delivered	via	 tail	vein	 injection	on	Day	20.	The	animal	subjects	were	imaged	24	hours	after	injection	to	allow	for	biological	uptake.									 A	high-resolution	anatomical	scan	was	performed	first	using	bSSFP	(TR	=	8ms,	TE	=	4ms,	FA	=	30°,	4	phase	cycles,	matrix	=	256	x	170	x	170,	FOV	=	38.4	x	25.5	x	25.5	mm3,	scan	time	64	min).	Signal	time	course	data	were	provided	by	a	3D	TurboSPI	scan	accelerated	 by	 compressed	 sensing16	 (TR=250	 ms,	 TEeffective	 =	 10	 ms,	 ETL=8,	ESP=10ms,	matrix	=	96	x	96	x	48,	FOV=30	x	30	x	30	mm3,	acceleration	factor	=	8,	Fat	Sat	=	90°	sinc,	scan	time	29	min).	A	matched	parameter	fast	spin	echo	(FSE)	pre-scan	(scan	 time	 2.5	 min)	 preceded	 the	 3D	 TurboSPI	 sequence	 to	 guide	 the	 pseudo	randomly	 under-sampled	 acquisition	 and	 constrain	 the	 final	 compressed	 sensing	(CS)	reconstruction.									 After	 the	 CS	 reconstruction	 was	 performed	 using	 an	 in-house	 Matlab	program16,	the	time	course	data	were	fit	for	each	voxel	using	three	techniques:	single-decay	(Eq.	1),	exclusion	(as	in	in	vitro)	study,	and	dual-decay	(Eq.	2).		3D	bSSFP	and	R2*	data	were	co-registered	rigidly	using	the	FSE	scan	as	an	intermediary	and	fused	in	VivoQuant	(inviCRO,	Boston	MA)	for	visualization.			
Results:			
In	Silico							 Figure	4	gives	an	example	of	the	fitted	time	course	for	one	set	of	parameters.		Though	 the	 split	 real-imaginary	 function	 (Figure	 4b)	 is	 less	 visually	 intuitive	 as	 a	signal	time	course	than	the	complex	equivalent	(Figure	4a),	this	allows	a	bounded	fit	that	provides	better	performance	 for	noisy	data	while	still	matching	well	with	 the	simulation	(RMSE	=	9.4	x	10-4),				 The	accuracy	of	fat	estimation	over	a	range	of	simulated	fat	fractions	is	shown	in	Figure	5a,	while	Figure	5b	shows	the	stability	of	the	water	T2*	parameter	estimate	across	the	range	of	fat	fractions	for	three	different	perturber	volume	fractions.	When	fit	properly,	the	water	and	fat	terms	are	separated	appropriately,	and	T2w*	is	invariant	to	fat	content	while	changing	appropriately	at	different	volume	fractions	(i.e.	different	cell	 densities).	 This	 stable	 behaviour	 is	 observed	 from	 0-99%	 fat	 (with	 a	 slight	deviation	at	fat	=	5%)	suggesting	that	the	dual-decay	model	is	stable	for	mixed	voxels,	but	the	fit	deteriorates	at	100%	fat	since	the	model	is	no	longer	appropriate.	Standard	deviations	(σ)	of	the	T2*	measurements	from	0-99%	fat	are	σ	=0.23ms	(ζ	=	1.0	x	10-5),	0.16ms	(ζ	=	1.5	x	10-5),	and	0.12ms	(ζ	=	2.0	x	10-5),	reflecting	how	fit	performance	improves	with	increased	R2*	effect.								 White	Gaussian	noise	was	added	 to	 simulated	TurboSPI	data	 to	 investigate	noise	performance	of	the	proposed	dual-decay	model.		This	model	was	evaluated	for	20	different	repetitions	each	at	five	fat	fractions,	with	temporal	signal-to-noise	ratios	(tSNR)	of	1	to	40.		The	mean	and	standard	deviation	of	the	resulting	fat	fraction	and	T2*	 estimates	 are	 reported	 in	 Figure	 6.	While	 the	 dual-decay	model	 exhibits	 poor	
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predictive	performance	for	very	low	tSNR,	the	mean	estimates	plateau	at	tSNR	~	20.	An	in	vivo	TurboSPI	scan	typically	has	tSNR	>40.		
In	Vitro										 R2*	 maps	 calculated	 using	 the	 dual-decay	 model	 were	 compared	 to	 those	calculated	using	 the	exclusion	method	 (mono-exponential	decay	while	 eliminating	voxels	with	fat	periodicity).	Ideally,	the	“no	cell	(NC)”	tubes	should	have	low	R2w*,	the	mixed	fat/water	tubes	should	have	equal	R2w*	to	reflect	their	equal	cell	densities,	and	fat	 saturation	 should	 not	 affect	 R2w*.	 Figure	 7	 shows	 example	 R2w*	 maps	 for	 the	phantoms.	The	exclusion	technique	without	fat	saturation	removes	all	voxels	with	fat	content	>	15%.	While	this	is	valid	for	the	NC	tubes,	 it	 is	 inaccurate	for	those	tubes	with	mixed	voxels,	since	the	R2w*	values	used	to	assess	cell	density	are	not	computed.		The	 use	 of	 fat	 saturation	 appears	 to	 further	 reduce	 accuracy	 due	 to	 incomplete	removal	of	fat	signal.		The	dual-decay	technique	results	in	more	stable	R2w*	estimates	for	 the	mixed	 tubes	 and	 predicts	 lower	 R2w*	 values	 for	 the	NC	 controls,	 although	ideally	these	two	tubes	would	have	even	lower	estimates.							 The	 findings	 for	 the	 fat/water/cell	 mixture	 phantoms	 are	 summarized	 in	Figure	8,	where	the	R2w*	estimates	are	plotted	against	the	known	fat	fractions	to	test	the	metric’s	invariance	to	fat	content.	Here	we	show	parameters	estimated	using	a	common-decay	 (where	R2w*	=	R2f*)	model	 alongside	 the	dual-decay	and	exclusion	techniques.	 The	 dual-decay	 gives	 the	 most	 stable	 R2w*	 estimates	 across	 most	 fat	fractions,	while	the	reliability	of	the	exclusion	method	deteriorates	for	fat	≥15%,	and	the	 estimated	 R2*	 from	 the	 common-decay	 model	 decreases	 with	 increased	 fat	content.	We	note	that	acquiring	data	with	a	fat	saturation	pulse	results	in	slight	R2w*	underestimates	from	the	dual-decay	model,	and	wildly	inconsistent	R2w*	estimates	from	the	exclusion	technique.			
In	Vivo						 Finally,	the	dual-decay	model	was	tested	on	in	vivo	data	and	compared	to	the	single-decay	 and	 exclusion	 techniques.	 As	 shown	 in	 Figure	 9,	 the	 proposed	 dual-decay	technique	exhibits	fewer	erroneously	fit	voxels	than	the	single-decay	model,	but	more	than	the	exclusion	method.	However,	the	strict	conditions	imposed	by	the	exclusion	technique	results	in	drastic	underestimates	for	potentially	mixed	voxels	(as	illustrated	in	the	in	vitro	data)	and,	therefore,	no	R2w*	values	above	threshold	are	seen	in	 the	 tumor	 or	 adjacent	 lymph	 node,	 which	 is	 not	 consistent	 with	 the	 known	behavior	of	these	loaded	cells.		
Discussion									 The	proposed	comprehensive	dual-decay	Dixon	model	successfully	provides	accurate	estimates	of	T2w*	despite	changing	fat	content	in	simulated	TurboSPI	data.	Simultaneously	estimating	these	parameters	improves	accuracy	in	both	fat	fraction	and	T2*	measurements,	though	only	the	T2*	measurement	is	the	focus	of	this	work.	We	 investigated	 T2w*	 stability	 with	 respect	 to	 fat	 content	 for	 different	 levels	 of	physical	complexity:	data	that	neglected	T2f*,	data	with	a	common	T2*,	and	finally	for	the	most	physically	descriptive	case	of	 independent	T2w*	and	T2f*.	The	T2w*	values	estimated	 using	 the	 dual-decay	 model	 compared	 favorably	 to	 gold	 standards	
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obtained	from	using	a	simple	mono-exponential	fit	on	a	simulated	time	course	with	no	added	fat.	The	in	silico	results	suggest	that	the	proposed	model	should	give	T2w*	estimates	that	are	invariant	to	voxel	fat	content	and	thus	result	in	more	accurate	and	descriptive	R2*	maps.			 A	limitation	of	the	in	silico	work	was	that	it	neglects	the	effects	of	unintended	(i.e.	 not	 from	SPIO)	B0	 inhomogeneity	 to	 investigate	 the	 fit	 response.	However,	 in	translating	the	model	to	non-idealized	data,	we	allowed	Δωwf	Δt	and	θτΔt	to	vary	to	reflect	the	time-dependent	B0	phase	effect	(ϕ=γΔB0Δt).	This	should	be	sufficient	for	the	current	 investigation,	 since	 the	goal	 is	not	 to	explicitly	decouple	or	map	 these	parameters,	but	to	consider	their	combined	effect.		Reeder	 and	 Horng26,28	 acknowledge	 that	 a	 dual-decay	 model	 provides	 a	 more	accurate	 description	 of	 the	 physical	 system,	 but	 is	 hindered	 by	 poor	 noise	performance	 from	 adding	 more	 fit	 parameters.	 When	 using	 a	 common	 T2*,	 as	suggested	originally	by	Glover27,	if	T2f*	≠	T2w*,	the	common	T2*	will	be	an	average	that	changes	with	fat	content,	which	is	detrimental	to	quantification	of	T2*.	We	tested	this	in	 Fig.	 8	 but	 found	 that,	 in	 the	 in	 vitro	 and	 in	 silico	 experiments,	 using	 the	more	physically	descriptive	“dual”	T2*	model25,26	gave	more	accurate	results,	even	though	it	 added	 another	 parameter.	 Naturally,	 increasing	 the	 number	 of	 unknowns	necessitates	 an	 increase	 in	 the	 number	 of	 measurements,	 but	 TurboSPI	 data	(simulated	or	otherwise)	 are	well	 equipped	 to	provide	 this	 since	~200	points	 are	routinely	used	in	the	fitting	region	for	real	data.	A	noise	performance	analysis	using	simulated	 Gaussian	 noise	 indicates	 that	 fit	 results	 stabilize	 at	 tSNR	 =	 20	 for	 both	common	and	separate	T2*.								 When	 applied	 to	 in	 vitro	 data,	 as	 predicted,	 the	 dual-decay	 signal	 model	provided	R2w*	estimates	that	were	more	resistant	to	changes	due	to	high	fat	content	in	mixed	voxels,	as	compared	to	the	exclusion	technique	or	common-decay	model.	The	 benefits	 of	 using	 a	 more	 comprehensive	 model	 becomes	 apparent	 when	 fat	content	rises	above	≥15%;	both	techniques	were	similarly	stable	in	their	estimates	for	fat	<15%,	but	the	standard	deviation	of	the	exclusion	technique	increased	at	15%,	and	 accuracy	 deteriorated	 further	 for	 higher	 fat	 contents.	When	 using	 a	 common	decay	 rate,	 we	 note	 that	 the	 R2*	 estimates	 decrease	 linearly	 with	 increased	 fat	content,	reflecting	a	mixing	of	the	two	different	relaxation	rates.									 Fat	saturation	had	a	significant	impact	on	R2w*	estimates	when	using	both	the	exclusion	and	common-decay	techniques.	Without	fat	saturation,	mixed	voxels	with	fat	 content	 >15%	 were	 removed	 from	 the	 map	 calculated	 using	 the	 exclusion	technique,	meaning	 that	 any	 SPIO-labeled	 cells	 present	will	 be	 ignored.	 	 After	 fat	saturation,	the	exclusion	method	gave	over-estimates	of	R2w*	for	20%	and	30%	fat	and	eliminated	mixed	voxels	with	fat	content	of	40%.	When	fat	 is	present	 in	small	quantities,	 the	 fat	 saturation	 pulse	 suppresses	 enough	 of	 the	 fat	 signal	 to	 evade	exclusion,	but	the	remaining	fat	signal	still	influences	the	overall	amplitude	near	the	spin	 echo,	 resulting	 in	 overestimated	 R2w*.	 The	 R2w*	 estimate	 should	 ideally	 be	invariant	to	a	voxel’s	fat	content,	and	these	in	vitro	data	demonstrate	the	improved	accuracy	of	the	proposed	dual-decay	technique.	In	addition	to	being	more	invariant	to	fat	content,	the	R2w*	measurements	from	dual-decay	were	also	less	affected	by	the	fat	saturation	pulse.	However,	while	the	effect	was	not	as	severe,	fat	saturation	did	consistently	result	in	slight	underestimates	of	R2w*.	These	underestimates	were	likely	
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due	to	SPIO	induced	line	broadening	in	the	sample	and	partial	saturation	of	the	water	peak,	even	when	using	a	spectrally	selective	fat	saturation	pulse.														In	vitro	findings	suggest	that	the	dual-decay	model	should	result	in	fewer	mis-fit	voxels,	improving	in	vivo	specificity	while	maintaining	sensitivity	to	mixed	voxels.	Other	techniques	could	assist	in	further	discriminating	SPIO	labeled	cells	from	pure	fat;	 for	 example,	 future	 implementations	may	 consider	 an	 adaptive	 approach	 that	uses	fat	content	to	prescribe	the	fitting	technique	on	a	voxel-by-voxel	basis.	That	is,	the	dual	decay	model	 could	be	used	 as	 a	 first-pass	 fitting	method,	with	 the	 single	decay	model	re-applied	to	voxels	below	a	certain	fat	threshold,	and	with	voxels	above	a	certain	fat	threshold	eliminated.	This	adaptive	approach	would	provide	the	benefits	of	each	technique.																		The	 present	 work	 uses	 a	 simplified	 lipid	 spectral	 model.	 Comprehensive	spectral	modeling	is	less	crucial	to	this	work	than	in	applications	that	require	more	accurate	fat	quantification.	The	reasoning	is	similar	to	those	fat-focused	publications	which	note	that,	while	using	separate	R2w*	and	R2f*	values	is	more	physically	accurate,	the	benefit	is	not	worth	the	additional	model	parameter.	Since	this	work	focuses	on	accurate	R2*	quantification,	multi-peak	fat	spectra	may	not	be	beneficial	enough	to	be	worth	complicating	the	model.	Nonetheless,	it	is	a	potential	avenue	for	future	work.	Despite	the	limitations	noted	above,	the	proposed	technique	performed	well	on	in	vivo	data.	Figure	9	shows	in	vivo	R2w*	as	calculated	by	three	fitting	techniques	(single-decay,	 exclusion,	 dual-decay).	 The	 single-decay	 map	 clearly	 overestimates	R2w*,	and	thus	cell	density,	in	the	tumor.	While	the	exclusion	technique	exhibits	the	fewest	erroneously	fit	fat	voxels,	 it	simply	fits	far	fewer	voxels	overall.	The	 in	vitro	data	demonstrated	that	this	exclusion	technique	is	not	sensitive	to	voxels	with	mixed	content.	Therefore,	this	map	certainly	excludes	some	voxels	containing	SPIO-labeled	cells	and	would	underestimate	cell	density.	In	the	tumor,	the	bSSFP	image	shows	a	hypo-intense	region	that	is	not	shown	to	have	high	R2w*	by	any	mapping	technique	–	this	is	likely	necrosis.	However,	there	are	hypo-intense	regions	which	have	high	R2*	on	the	single-decay	and	the	dual-decay	maps	but	are	nearly	ignored	by	the	exclusion	technique.	The	proposed	dual-decay	technique	is	less	sensitive	to	misidentification	of	fat	voxels	than	the	single-decay	fit	while	retaining	mixed	voxels	of	fat	and	iron	unlike	single-decay	with	post-hoc	exclusion.			
Conclusion		 The	principal	objective	of	 this	work	was	to	 investigate	the	adverse	effect	of	contaminant	 fat	 modulations	 in	 TurboSPI	 and	 propose	 corrective	 methods.	 R2*	estimates	should	be	invariant	to	fat	content,	but	single-species	mono-exponential	R2*	mapping	fails	in	the	presence	of	fat.	This	is	detrimental	to	in	vivo	cell	tracking	studies	that	measure	cell	density	via	R2*	mapping,	since	mixed-content	voxels	arise	in	tumors	and	lymph	nodes	surrounded	by	adipose	tissue.	In	silico	data	shows	that	R2*	estimates	are	 stable	 across	 most	 fat	 fractions	 if	 R2w*,	 R2f*	 and	 fat	 fraction	 are	 estimated	simultaneously	 using	 a	 modified	 dual-decay	 Dixon	 model.	 This	 finding	 was	corroborated	by	an	in	vitro	experiment	in	which	the	proposed	model	outperformed	previous	methods	when	SPIO-labeled	cells	are	present	with	fat	≥15%.	Preliminary	in	
vivo	 results	 indicate	positive	development	with	an	 improved	balance	of	 specificity	
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and	sensitivity.	Therefore,	 the	proposed	model	 is	a	promising	tool	 for	quantitative	TurboSPI	R2*	cell	tracking,	with	further	refinements	offering	the	possibility	of	even	higher	specificity	and	sensitivity.			
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Figures		
		
Figure	1:	Figure	reproduced	from	12.	Upper	row:	MRI	obtained	using	bSSFP.	Negative	contrast	in	the	center	of	the	flank	tumor	suggests	SPIO	uptake	or	necrosis.	Bottom	row:18F-fluorodeoxyglucose	(FDG)	PET/MRI	overlay	using	simultaneously	obtained	PET	data.	A	necrotic	core	is	confirmed	by	low	18F-FDG	activity	aligned	with	the	hypo-intense	region	on	the	MRI.		
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Figure	2:	Upper	row:	a)	bSSFP	MRI.	b)	R2*	map	(voxel	intensity	in	0	–	600s-1)	overlaid	on	the	axial	bSSFP	slice	to	show	distribution	of	R2*.	The	flank	tumour	ROI	is	highlighted	by	a	red	circle.		Bottom	row:		c)	TurboSPI	signal	time	course	from	a	typical	voxel	in	Region	1,	which	is	a	section	of	tumor	potentially	containing	SPIO	and	fat.		d)	A	typical	time	course	from	Region	2	indicates	signal	from	pure	fat	(oscillations	are	fat	specific).		e)	Time	courses	from	Region	3	in	the	lymph	node/adjacent	fat	pad	potentially	containing	fat	and	SPIO.				
	
Figure	3:	a)	Simulated	TurboSPI	signal	in	the	presence	of	SPIO.	Dashed	red	line	indicates	typical	R2*	fitting	region,	which	avoids	non-exponential	behavior	from	
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diffusion	near	the	spin	echo	peak.	b)	Simulated	TurboSPI	signal	with	15%	added	fat	signal.	Off	resonance	fat	causes	modulations	in	the	signal	time	course	such	that	mono-exponential	models	are	not	suitable	for	curve-fitting.	Blue	lines	indicate	the	experimental	acquisition	window.			
		
Figure	4:	a)	Normalized	simulated	complex	data	(magnitude	shown,	solid	black)	with	the	corresponding	fit	(dashed	blue).	The	simulation	is	shown	for	t	=	10	ms	to	12.5	ms	but	the	fit	is	performed	for	t	=	10.5	ms	to	12.5	ms	to	avoid	the	spin-echo	peak.		Simulation	parameters:	Fat	fraction	ff	=	0.15,	ζ	=	1.5	x	10-5,	R	=	8um,	Δχ	=	0.05,	no	T2*	effect	simulated	for	the	fat	species.		T2*	estimate	from	fit	=	4.38	ms,	gold	standard	for	same	parameters	but	ff	=	0	was	T2*	=	4.5	ms,		b)	The	same	simulated	data	with	concatenated	real	(black)	and	imaginary	(blue)	components,	and	corresponding	model	fit	(dashed	grey).		Same	parameters	as	in	(a)	but	with	a	simulated	T2*	=	15	ms	for	the	fat	species.		Water	T2*	estimate	from	fit	=	4.31	ms.		
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Figure	5:	a)	Fitted	fat	fraction	versus	input	fat	fraction	compared	to	an	identity	line	for	reference.	Estimates	fail	only	at	FF	extrema.	b)	Fitted	T2*	versus	input	fat	fraction	shows	stability	in	the	measurement	except	at	FF	extrema.	Decay	times	change	appropriately	with	volume	fraction.	Estimates	from	FF	=	0.5	
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Figure	6:	Results	of	fat	fraction	and	T2*	estimation	on	simulated	data	with	added	Gaussian	white	noise.		Left	panels:	mean	(a)	and	standard	deviation	(c)	of	fat	fraction	estimates	over	20	repetitions,	as	a	function	of	temporal	SNR	and	for	5	different	fat	fractions.		Right	panels:	mean	(b)	and	standard	deviation	(d)	of	water	T2*	estimates,	with	gold	standard	(noiseless,	no	fat)	T2*	=	4.50ms.		In	both	cases	the	parameter	estimates	stabilize	above	a	temporal	SNR	of	20.	
	
Figure	7:	Example	R2w*	maps	for	data	acquired	with	and	without	fat	saturation,	fitted	with	the	Exclusion	and	the	Dual-Decay	methods.		All	phantoms	have	equal	cell	concentration	(except	for	“no	cell”	(NC)	controls)	and	varying	fat	fraction	(FF).	Ideally,	NC	tubes	should	have	low	R2w*,	others	should	have	equal	R2w*,	and	fat	saturation	should	not	affect	R2w*.	Estimates	from	the	Dual-Decay	technique	are	stable	over	a	greater	range	of	FF	than	the	Exclusion	technique.		
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Figure	8:	R2w*	values	for	phantoms	with	equal	cell	density	but	varying	fat	content.	Values	were	estimated	using	1)	the	exclusion	method,	2)	a	common	decay	rate	model	(R2w*	=	R2f*),	and	3)	the	proposed	dual-decay	model.	Data	were	acquired	with	and	without	a	fat	saturation	pulse.	The	dual-decay	estimates	are	stable	over	the	widest	range	of	fat	content	and	are	least	affected	by	fat	saturation.	The	common	decay	method	results	in	R2*	estimates	that	decrease	with	fat	content,	as	predicted.	
	
Figure	9:		Preliminary	in	vivo	demonstration	of	R2*	maps	(overlays,	masked	to	tumor	region)	produced	by	single-decay,	exclusion,	and	the	proposed	dual-decay	fitting	techniques.	The	proposed	technique	results	in	fewer	erroneously	fitted	fat	voxels	than	the	single-decay	technique,	but	more	than	exclusion.	However,	as	illustrated	in	vitro,	the	exclusion	technique	underestimates	the	contribution	of	mixed	voxels.	
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Supplementary Materials 
Methods 
For previous experiments cited in 22 and shown in Figures 1 and 2 as supporting data, all in vivo 
data was acquired using the same C3 cancer model and injected CTLs as described in methods. 
Mice were imaged on a 3.0T preclinical MRI system with the same bSSFP sequence used as an 
anatomical reference as described for the other in vivo experiments. The PET data shown in 
Figure 1 was acquired at the same time as the MRI data using a nuPET insert (2 rings with silicon 
photomultiplier detectors; Cubresa, Winnipeg, MB) for the MRI system. The RF coil used for this 
experiment was a mouse body quad coil. Approximately 600uCi of 18F-fluorodeoxyglucose 
(FDG) was injected in the tail vein of the mouse prior to imaging. PET imaging was done 
simultaneously to MRI, with PET data acquisition beginning 50 minutes post-injection. The PET 
scan lasted for 30 minutes. PET data was reconstructed with a iterative maximum likelihood 
estimate OSMAPOSL algorithm (Cubresa).  
 
Results 
 
Supplementary Figure 1 – Results of fat fraction and T2* estimation on simulated data with 
added Gaussian white noise for T2F* = T2w* .  Left panels: mean (a) and standard deviation (c) of 
fat fraction estimates over 20 repetitions, as a function of temporal SNR and for 5 different fat 
fractions.  Right panels: mean (b) and standard deviation (d) of water T2* estimates, with gold 
standard (noiseless, no fat) T2* = 4.50ms.  In both cases the parameter estimates stabilize 
above a temporal SNR of 20.   
